Abstract
Background
Impaired immunological tolerance to commensal enteric flora is considered one possible pathogenic mechanism of inflammatory bowel disease (IBD). Given that regulatory T cells and Toll-like receptor (TLR)-positive cells are key actors in mucosal immune regulation, we aimed to identify the dynamics of these actors in the intestinal mucosa in relation to clinical improvement following selective leukapheresis treatment.
Methods
Ten patients with active IBD despite treatment with corticosteroids, immunomodulators, or anti-tumor necrosis factor therapy were assessed by immunohistochemical staining of colorectal mucosal biopsies obtained before and after five sessions (week 7) of granulocyte and monocyte adsorption apheresis (GCAP). The presence of FoxP3-positive regulatory T cells, macrophages, dendritic cells, and TLR-2 and-4 positive cells was determined in relation to short-(week 7) and long-term (week 52) clinical outcome data.
Results
Following GCAP, the number of FoxP3-(P = 0.012) and TLR-2 (P = 0.008)-positive cells significantly decreased in biopsies after 7 weeks, in parallel with both clinical improvement at week 7 and a longstanding response after 12 months.
Conclusions
Downregulation of FoxP3 and TLR-2 cells in the colorectal mucosa mirrors both short-and long-term improvement in patients with active IBD responding to GCAP. This observation suggests a potential role of these cells in the pathogenesis of IBD and the induction of immunological tolerance in the mucosa.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ohkusa T, Nomura T, Sato N. The role of bacterial infection in the pathogenesis of inflammatory bowel disease. Intern Med 2004;43:534–539.
Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868–1878.
Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, et al. Characteristics of intestinal dendritic cells in inflamatory bowel diseases. Gastroenterology 2005;129:50–65.
Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934–938.
Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjövall H, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006;12:447–456.
Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, et al. Analysis of FoxP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681–1691.
Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the fork-head transcription factor foxp3. Immunity 2005;22:329–341.
Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietink R, Rutgeers P, et al. Toll-like receptor-1,-2, and-6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006;12:1–8.
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, et al. Downregulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflamatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis 2006;21:493–504.
Rachmilewitz D. Coated mesalazine (5-amino-salicilic acid) versus sulphasalazine in treatment of active ulcerative colitis: a randomized trial. BMJ 1989;298:82–86.
Best WR, Becktel JM, Singleton JW. Rederived values of eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology 1979;77(4 Pt 2):843–846.
Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, et al. Granulocyte, monocyte/macrophage apheresis for inflamatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221–227.
Suri-Payer E, Fitzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol 2006;28:3–16.
Huehn J, Siegmund K, Lehmann JCU, Siewert C, Haubold U, Feuerer M, et al. Developmental stage, phenotype, and migration distinguish naive-and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004;199:303–313.
Denning TL, Qi H, König R, Scott KG, Naganuma M, Ernst PB. CD4+ T cells resembling regulatory T cells that inhibit chronic colitis differentiate in the absence of interactions between CD4 and class II MHC. J Immunol 2003;171:2279–2286.
Kelsen J, Agnholt J, Hoffmann HJ, Rømer JL, Hvas CL, Dahlerup JF. FoxP3+CD4+CD25+ T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn’s disease. Clin Exp Immunol 2005;141:549–557.
Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, et al. Characterization of FoxP3+ CD4+ CD25+ and IL-10-secreting CD4+ CD25+ T cells during cure of colitis. J Immunol 2006;177:5852–5860.
Yu QT, Satura M, Avanesyan A, Fleshner PR, Banham AH, Papadikis KA. Expression and functional characterization of FOXP3+CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2006;13:191–199.
Lundgren A, Strömberg E, Sjöling Å, Lindholm C, Enarsson K, Edebo A, et al. Mucosal FoxP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005;73:523–531.
Matsuguchi T, Musikacharoen T, Ogawa T, Yoshikai Y. Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 2000;165:5767–5772.
Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via toll-like receptor 2. J Med Microbiol 2004;53:735–740.
Opitz B, Schröder NWJ, Spreitzer I, Michelsen KS, Kirschning CJ, Hallatschek W, et al. Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-κB translocation. J Biol Chem 2001;276:22041–22047.
Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M. Antimicrobials in the management of inflamatory bowel disease. Digestion 2006;73Suppl 1:77–85.
Wang JH, Doyle M, Manning BJ, Di Wu Q, Blankson S, Redmond HP. Induction of bacterial lipoprotein tolerance is associated with suppression of toll-like receptor-2 expression. J Biol Chem 2002;277:36068–36075.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muratov, V., Ulfgren, AK., Engström, M. et al. Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis. J Gastroenterol 43, 277–282 (2008). https://doi.org/10.1007/s00535-007-2156-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-007-2156-3